CYP2C19 genotype-phenotype correlation: current insights and unanswered questions

Area of Science:

• Pharmacogenomics
• Drug Metabolism
• Enzyme Activity

Background:

• The CYP2C19 enzyme plays a key role in metabolizing numerous medications.
• Patient metabolizer status is typically predicted using CYP2C19 genotyping.
• Current genotyping methods often lack reliability due to a lack of ethnic diversity in research populations.

Purpose of the Study:

• To review factors influencing CYP2C19 phenotype prediction.
• To highlight the need for ethnically diverse research populations.
• To advocate for the development of inclusive clinical guidelines.

Main Methods:

• Literature review of CYP2C19 pharmacogenomics studies.
• Analysis of factors affecting CYP2C19 enzyme activity.
• Discussion of ethnic variations in drug metabolism.

Main Results:

• CYP2C19 genotyping shows limited predictive power for metabolizer status across diverse populations.
• Evidence supporting current predictions is primarily derived from European ancestry cohorts.
• Significant ethnic variations in CYP2C19 phenotype are suggested.

Conclusions:

• Existing CYP2C19 genotyping guidelines may not be universally applicable.
• Incorporating ethnically diverse populations into pharmacogenomic studies is essential.
• Developing tailored clinical guidelines is necessary for equitable and effective drug therapy.